<DOC>
	<DOCNO>NCT00447187</DOCNO>
	<brief_summary>This pivotal trial determine whether LX201 reduces likelihood graft rejection episode follow corneal transplantation patient high immunological risk rejection .</brief_summary>
	<brief_title>Study Assess Efficacy Safety LX201 Prevention Corneal Allograft Rejection Episodes Graft Failure Subjects Increased Immunological Risk</brief_title>
	<detailed_description>LX201 novel sustained-release silicone implant contain 30 % cyclosporine A weight . LX201 intend surgical episcleral placement eye . The study Phase 2/3 , multi-center , placebo-controlled , randomize , parallel-group , dose-ranging study LX201 prevention corneal allograft rejection graft failure follow penetrate keratoplasty LX201 implantation . Subjects follow outpatient set safety efficacy 4-6 week interval 52 week follow transplantation surgery . After Visit 12 ( Week 52 ) , subject USA India implant study eye follow safety least per year 2-year period time implant removal . For subject USA India , implant remove time prior 3 year safety follow-up , subject final safety follow visit 3 month post removal . In Germany , implant remove Week 52 3-month safety follow-up period removal .</detailed_description>
	<mesh_term>Corneal Diseases</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Subjects candidate corneal transplant increase immunological risk graft failure , evidence one following : ≥ 1 quadrant deep corneal vascularization verifiable history graft failure due rejection position graft &lt; 1 mm limbus Any condition would greatly increase risk nonrejection graft failure StevensJohnson syndrome , xerophthalmia severe exposure keratitis . Schirmer 's test ≤ 5 mm 1 minute Clinical evidence limbal stem cell deficiency History active herpes simplex virus keratitis acute corneal infection Subjects &gt; 3 fail graft study eye Uncontrolled glaucoma evidence intraocular pressure &gt; 21 mmHg maximal medical therapy Clinically suspect confirm ocular lymphoma Treatment systemic immunosuppressive regimen within previous 30 day ; systemic prednisone ( equivalent ) ≤ 10 mg daily , however , permit . Any implantable corticosteroideluting device ( e.g. , Retisert™ , Posurdex® , Medidur™ , Ivation™ TA intravitreal implant ) Subjects periodically require highdose systemic steroid treatment ( e.g. , exacerbation chronic obstructive pulmonary disease ) . Subjects receive treatment monoclonal antibody biologic therapy within previous 90 day alemtuzumab within previous 12 month History herpes zoster varicella infection within 6 week prior enrollment , chicken pox exposure within 21 day enrollment Seropositivity human immunodeficiency virus ( HIV ) Previous exposure know contraindication administration cyclosporine Recipients solid organ transplant Currently pregnant lactate Active , extraocular and/or systemic infection require prolong chronic use antimicrobial agent presence active hepatitis A , B C Severe anemia ( hemoglobin &lt; 6 g/dL ) , leukopenia ( white blood cell count [ WBC ] &lt; 2500 mm3 ) , thrombocytopenia ( platelet count &lt; 80,000 mm3 ) , polycythemia ( hematocrit [ Hct ] &gt; 54 % [ male ] Hct &gt; 49 % [ female ] ) clinically significant coagulopathy Current malignancy history malignancy ( within previous 5 year ) except nonmetastatic basal squamous cell carcinoma skin carcinomainsitu cervix treat successfully Active peptic ulcer disease Comorbid condition require immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>corneal graft failure</keyword>
	<keyword>corneal graft rejection</keyword>
	<keyword>corneal transplant rejection</keyword>
</DOC>